GenomeDx

The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.

The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.

A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. 

The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.

The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.

GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.

Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.

Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies. 

Launching the new biopsy-based version of Decipher, GenomeDx enters more direct competition with tests offered by Myriad Genetics and Genomic Health.

The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.